Abstract
Cytotoxic drugs may have specific effects on oncogenes and their downstream targets. Increase of cancer cell sensitivity due to repression of an oncogene downstream target can be specifically addressed by combined precision chemotherapy, increasing the therapeutic index of chemotherapy and overcoming resistance to highly selective targeted therapies.
©2014 AACR
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Camptothecin / analogs & derivatives*
-
Camptothecin / pharmacology
-
DNA Damage / drug effects*
-
Dioxoles / pharmacology*
-
Female
-
Humans
-
Irinotecan
-
Oncogene Proteins, Fusion / antagonists & inhibitors*
-
Proto-Oncogene Protein c-fli-1 / antagonists & inhibitors*
-
RNA-Binding Protein EWS / antagonists & inhibitors*
-
Sarcoma, Ewing / genetics*
-
Sarcoma, Ewing / metabolism*
-
Tetrahydroisoquinolines / pharmacology*
-
Trabectedin
Substances
-
Antineoplastic Agents
-
Dioxoles
-
EWS-FLI fusion protein
-
Oncogene Proteins, Fusion
-
Proto-Oncogene Protein c-fli-1
-
RNA-Binding Protein EWS
-
Tetrahydroisoquinolines
-
Irinotecan
-
Trabectedin
-
Camptothecin